CoChat

Mycoplasma pneumoniae: Current knowledge on macrolide resistance and treatment.

Pereyre, Sabine, Goret, Julien, Bébéar, Cécile · 2016 · Frontiers in Microbiology
Cited by 272

The DOI matches its Crossref record.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2016.00974

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 93

  1. Akaike, 2012, In vitro activities of 11 antimicrobial agents against macrolide-resistant Mycoplasma pneumoniae isolates from pediatric patients: results from a multicenter surveillance study, Jpn. J. Infect. Dis., 65, 535, 10.7883/yoken.65.535 · doi:10.7883/yoken.65.535
  2. Atkinson, 2008, Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections, FEMS Microbiol. Rev., 32, 956, 10.1111/j.1574-6976.2008.00129.x · DOI · Paper page
  3. Atkinson, 2011, Stevens-Johnson syndrome in a boy with macrolide-resistant Mycoplasma pneumoniae pneumonia, Pediatrics, 127, e1605, 10.1542/peds.2010-2624 · DOI
  4. Averbuch, 2011, Macrolide resistance, Mycoplasma pneumoniae, Israel, 2010. Emerging Infect. Dis., 17, 1079, 10.3201/eid/1706.101558 · doi:10.3201/eid/1706.101558
  5. Bebear, 2012, Editorial commentary: infections due to macrolide-resistant Mycoplasma pneumoniae: now what?, Clin. Infect. Dis., 55, 1650, 10.1093/cid/cis791 · doi:10.1093/cid/cis791
  6. Bébéar, 2005, Antimicrobial therapy and antimicrobial resistance, Mycoplasmas Molecular Biology Pathogenicity and Strategies for Control, 535
  7. Bébéar, 2005, Mechanisms of drug resistance, Mycoplasma pneumoniae. Curr. Drug Targets Infect. Disord., 5, 263, 10.2174/1568005054880109 · doi:10.2174/1568005054880109
  8. Bébéar, 2011, Mycoplasma pneumoniae: susceptibility and resistance to antibiotics, Future Microbiol., 6, 423, 10.2217/fmb.11.18 · DOI · Paper page
  9. Benitez, 2012, Multilocus variable-number tandem-repeat analysis of Mycoplasma pneumoniae clinical isolates from 1962 to the present: a retrospective study, J. Clin. Microbiol., 50, 3620, 10.1128/JCM.01755-12 · DOI
  10. Bissessor, 2015, Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort, and response of azithromycin failures to alternative antibiotic regimens, Clin. Infect. Dis., 60, 1228, 10.1093/cid/ciu1162 · DOI · Paper page
  11. Bradley, 2011, The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, Clin. Infect. Dis., 53, e25, 10.1093/cid/cir531 · DOI · Paper page
  12. Brown, 2015, Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015, Euro. Surveill., 20, 30078, 10.2807/1560-7917.ES.2015.20.48.30078 · doi:10.2807/1560-7917.es.2015.20.48.30078
  13. Cao, 2010, High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China, Clin. Infect. Dis., 51, 189, 10.1086/653535 · DOI · Paper page
  14. Cardinale, 2013, Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children, J. Clin. Microbiol., 51, 723, 10.1128/JCM.02840-12 · DOI
  15. Cardinale, 2011, Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia, Eur. Respir. J., 37, 1522, 10.1183/09031936.00172510 · doi:10.1183/09031936.00172510
  16. Chalker, 2015, International Mycoplasma pneumoniae typing study: interpretation of M. pneumoniae multilocus variable-number tandem-repeat analysis, New Microb. New Infect., 7, 37, 10.1016/j.nmni.2015.05.005 · doi:10.1016/j.nmni.2015.05.005
  17. Chalker, 2012, Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012, Euro. Surveill., 17, 20081, 10.2807/ese.17.06.20081-en · doi:10.2807/ese.17.06.20081-en
  18. Chalker, 2011, Increased incidence of Mycoplasma pneumoniae infection in England and Wales in 2010: multilocus variable number tandem repeat analysis typing and macrolide susceptibility, Euro Surveill., 16, 19865, 10.2807/ese.16.19.19865-en · doi:10.2807/ese.16.19.19865-en
  19. Chironna, 2011, Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children, J. Antimicrob. Chemother., 66, 734, 10.1093/jac/dkr003 · DOI
  20. Couldwell, 2013, Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance, Int. J. STD AIDS., 24, 822, 10.1177/0956462413502008 · DOI · Paper page
  21. Critchley, 2002, In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe, Clin. Microbiol. Infect., 8, 214, 10.1046/j.1469-0691.2002.00392.x · doi:10.1046/j.1469-0691.2002.00392.x
  22. Dégrange, 2009, Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of Mycoplasma pneumoniae, J. Clin. Microbiol., 47, 914, 10.1128/JCM.01935-08 · DOI
  23. Degrange, 2008, Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae, J. Antimicrob. Chemother., 61, 1390, 10.1093/jac/dkn118 · DOI
  24. Diaz, 2015a, Molecular detection and characterization of Mycoplasma pneumoniae among patients hospitalized with community-acquired pneumonia in the United States, Open Forum Infect. Dis., 2, ofv106, 10.1093/ofid/ofv106 · DOI
  25. Diaz, 2015b, Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013, J. Clin. Microbiol., 53, 124, 10.1128/JCM.02597-14 · DOI
  26. Dumke, 2013, Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012, Antimicrob. Agents Chemother., 57, 3460, 10.1128/AAC.00706-13 · doi:10.1128/aac.00706-13
  27. Dumke, 2015, Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012, Emerg. Infect. Dis., 21, 426, 10.3201/eid2103.140927 · doi:10.3201/eid2103.140927
  28. Dumke, 2014, Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia, Int. J. Infect. Dis., 29, 197, 10.1016/j.ijid.2014.07.014 · doi:10.1016/j.ijid.2014.07.014
  29. Dumke, 2010, Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany, Clin. Microbiol. Infect., 16, 613, 10.1111/j.1469-0691.2009.02968.x · doi:10.1111/j.1469-0691.2009.02968.x
  30. Eshaghi, 2013, Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011, Emerg. Infect. Dis., 19, 1525, 10.3201/eid1909.121466 · doi:10.3201/eid1909.121466
  31. Esposito, 2011, Levofloxacin for the treatment of Mycoplasma pneumoniae-associated meningoencephalitis in childhood, Int. J. Antimicrob. Agents., 37, 472, 10.1016/j.ijantimicag.2011.01.008 · DOI
  32. Ferguson, 2013, Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK, J. Med. Microbiol., 62, 1876, 10.1099/jmm.0.066191-0 · DOI
  33. Godron, 2013, Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection, Pediatr. Nephrol., 28, 2057, 10.1007/s00467-013-2541-5 · DOI
  34. Gruson, 2005, In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively, Antimicrob. Agents Chemother., 49, 1190, 10.1128/AAC.49.3.1190-1193.2005 · doi:10.1128/aac.49.3.1190-1193.2005
  35. Hantz, 2012, Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child, J. Clin. Microbiol., 50, 3402, 10.1128/JCM.01248-12 · DOI
  36. Harris, 2011, British Thoracic Society guidelines for the management of community acquired pneumonia in children: update, Thorax, 66, ii1, 10.1136/thoraxjnl-2011-200598 · DOI · Paper page
  37. Ho, 2015, Emergence of macrolide-resistant Mycoplasma pneumoniae in Hong Kong is linked to increasing macrolide resistance in multilocus variable-number tandem-repeat analysis type 4-5-7-2, J. Clin. Microbiol., 53, 3560, 10.1128/JCM.01983-15 · doi:10.1128/jcm.01983-15
  38. Hong, 2013, Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011, Emerg. Infect. Dis., 19, 1281, 10.3201/eid1908.121455 · doi:10.3201/eid1908.121455
  39. Ishiguro, 2015, Regional differences in prevalence of macrolide-resistant Mycoplasma pneumoniae in Hokkaido, Japan, Jpn. J. Infect. Dis, 69, 186, 10.7883/yoken.JJID.2015.054 · DOI
  40. Ji, 2014, Single-nucleotide polymorphism PCR for the detection of Mycoplasma pneumoniae and determination of macrolide resistance in respiratory samples, J. Microbiol. Methods., 102, 32, 10.1016/j.mimet.2014.04.009 · doi:10.1016/j.mimet.2014.04.009
  41. Kawai, 2013, Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients, Antimicrob. Agents Chemother., 57, 4046, 10.1128/AAC.00663-13 · DOI
  42. Kogoj, 2015, Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014, Euro Surveill., 20, 30018, 10.2807/1560-7917.ES.2015.20.37.30018 · doi:10.2807/1560-7917.es.2015.20.37.30018
  43. Lin, 2010, Nested PCR-linked capillary electrophoresis and single-strand conformation polymorphisms for detection of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, J. Clin. Microbiol., 48, 4567, 10.1128/JCM.00400-10 · DOI
  44. Liu, 2010, Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China, Diagn. Microbiol. Infect. Dis., 67, 355, 10.1016/j.diagmicrobio.2010.03.004 · DOI
  45. Liu, 2012, Multiclonal origin of macrolide-resistant Mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysis, J. Clin. Microbiol., 50, 2793, 10.1128/JCM.00678-12 · DOI
  46. Mandell, 2007, Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults., Clin. Infect. Dis., 44, S27, 10.1086/511159 · DOI · Paper page
  47. Matsubara, 2009, A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients, J. Infect. Chemother., 15, 380, 10.1007/s10156-009-0715-7 · doi:10.1007/s10156-009-0715-7
  48. Matsuda, 2013, Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan, BMC Infect. Dis., 13, 591, 10.1186/1471-2334-13-591 · doi:10.1186/1471-2334-13-591
  49. Matsuoka, 2004, Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan, Antimicrob. Agents Chemother., 48, 4624, 10.1128/AAC.48.12.4624-4630.2004 · DOI · Paper page
  50. Meyer Sauteur, 2014, Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland, Swiss Med. Wkly., 144, w14041, 10.4414/smw.2014.14041 · doi:10.4414/smw.2014.14041
  51. Meyer Sauteur, 2012, Neuroinvasive Mycoplasma pneumoniae infection without intrathecal antibody response, Pediatr. Infect. Dis. J., 31, 1199, 10.1097/INF.0b013e318266abff · DOI
  52. Miyashita, 2013, Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy, Antimicrob. Agents Chemother., 57, 5181, 10.1128/AAC.00737-13 · doi:10.1128/aac.00737-13
  53. Morozumi, 2008, Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia, Antimicrob. Agents Chemother., 52, 348, 10.1128/AAC.00779-07 · DOI · Paper page
  54. Morozumi, 2010, Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia, J. Infect. Chemother., 16, 78, 10.1007/s10156-009-0021-4 · DOI · Paper page
  55. Niitu, 1970, Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics, J. Pediatr., 76, 438, 10.1016/S0022-3476(70)80485-1 · DOI
  56. Nilsson, 2008, Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection, BMC Microbiol., 8, 93, 10.1186/1471-2180-8-93 · DOI · Paper page
  57. Okada, 2012, Rapid effectiveness of minocycline or doxyxycline against macrolide-resistant Mycoplasma pneumoniae infection in a outbreak among japanese children, Clin. Infect. Dis., 55, 1642, 10.1093/cid/cis784 · DOI · Paper page
  58. Pereyre, 2012, The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel, PLoS ONE, 7, e38585, 10.1371/journal.pone.0038585 · doi:10.1371/journal.pone.0038585
  59. Pereyre, 2007, First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years, J. Clin. Microbiol., 45, 3534, 10.1128/JCM.01345-07 · DOI
  60. Pereyre, 2004a, In vitro, 48, 460, 10.1128/AAC.48.2.460-465.2004 · DOI
  61. Pereyre, 2004b, In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas, Antimicrob. Agents Chemother., 48, 3165, 10.1128/AAC.48.8.3165-3168.2004 · doi:10.1128/aac.48.8.3165-3168.2004
  62. Pereyre, 2013, The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains, Clin. Microbiol. Infect., 19, E212, 10.1111/1469-0691.12107 · doi:10.1111/1469-0691.12107
  63. Peuchant, 2009, Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis, J. Antimicrob. Chemother., 64, 52, 10.1093/jac/dkp160 · DOI
  64. Pucci, 2011, In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens, Antimicrob. Agents Chemother., 55, 2860, 10.1128/AAC.01666-10 · DOI
  65. Rocha, 2002, Genomic repeats, genome plasticity and the dynamics of Mycoplasma evolution, Nucleic Acids Res., 30, 2031, 10.1093/nar/30.9.2031 · DOI · Paper page
  66. Sader, 2012, Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs), J. Antimicrob. Chemother., 67, 1170, 10.1093/jac/dks001 · doi:10.1093/jac/dks001
  67. Sakata, 2012, Clinical efficacy of tosufloxacin in children with pneumonia due to Mycoplasma pneumoniae, Jpn. J. Antibiot., 65, 173
  68. Scapini, 2008, Confirmed Mycoplasma pneumoniae endocarditis, Emerging Infect. Dis., 14, 1664, 10.3201/eid1410.080157 · doi:10.3201/eid1410.080157
  69. Spuesens, 2010, Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing, J. Microbiol. Methods., 82, 214, 10.1016/j.mimet.2010.06.004 · doi:10.1016/j.mimet.2010.06.004
  70. Spuesens, 2012, Macrolide-resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands, J. Clin. Microbiol., 50, 1999, 10.1128/JCM.00400-12 · DOI
  71. Stopler, 1986, Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B, J. Antimicrob. Chemother., 18, 359, 10.1093/jac/18.3.359 · DOI
  72. Sun, 2013, Multiple-locus variable-number tandem-repeat analysis of Mycoplasma pneumoniae clinical specimens and proposal for amendment of MLVA nomenclature, PLoS ONE., 8, e64607, 10.1371/journal.pone.0064607 · DOI
  73. Suzuki, 2006, Clinical Evaluation of Macrolide-Resistant, Mycoplasma pneumoniae. Antimicrob. Agents Chemother., 50, 709, 10.1128/AAC.50.2.709-712.2006 · DOI · Paper page
  74. Uldum, 2012, Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011, Euro. Surveill., 17, 20073, 10.2807/ese.17.05.20073-en · doi:10.2807/ese.17.05.20073-en
  75. Waites, 2011, Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas : Approved Guideline.
  76. Waites, 2013, Chemotherapy of Mycoplasma and Ureaplasma infections
  77. Waites, 2009, Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101, Antimicrob. Agents Chemother., 53, 2139, 10.1128/AAC.00090-09 · DOI
  78. Waites, 2015, In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas, Antimicrob. Agents Chemother., 59, 3627, 10.1128/AAC.04945-14 · doi:10.1128/aac.04945-14
  79. Wolff, 2008, Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis, Antimicrob. Agents Chemother., 52, 3542, 10.1128/AAC.00582-08 · DOI · Paper page
  80. Woodhead, 2011, Guidelines for the management of adult lower respiratory tract infections–full version., Clin. Microbiol. Infect., 17, E1, 10.1111/j.1469-0691.2011.03672.x · DOI · Paper page
  81. Wu, 2013, Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan, Pediatr. Pulmonol., 48, 904, 10.1002/ppul.22706 · DOI
  82. Xin, 2009, Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China, Antimicrob. Agents Chemother., 53, 2158, 10.1128/AAC.01563-08 · doi:10.1128/aac.01563-08
  83. Xue, 2014, Molecular characterizations of PCR-positive Mycoplasma pneumoniae specimens collected from Australia and China, J. Clin. Microbiol., 52, 1478, 10.1128/JCM.03366-13 · doi:10.1128/jcm.03366-13
  84. Yamada, 2012, Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States, Pediatr. Infect. Dis. J., 31, 409, 10.1097/INF.0b013e318247f3e0 · doi:10.1097/inf.0b013e318247f3e0
  85. Yamazaki, 2007, Activity of garenoxacin against macrolide-susceptible and -resistant Mycoplasma pneumoniae, Antimicrob. Agents Chemother., 51, 2278, 10.1128/AAC.01561-06 · DOI
  86. Yan, 2015, Comparison of molecular characteristics of Mycoplasma pneumoniae collected from, U.S. and China, J. Clin. Microbiol, 53, 3891, 10.1128/JCM.02468-15 · DOI
  87. Yan, 2014, A single-tube multiple-locus variable-number tandem-repeat analysis of Mycoplasma pneumoniae clinical specimens by use of multiplex PCR-capillary electrophoresis, J. Clin. Microbiol., 52, 4168, 10.1128/JCM.02178-14 · DOI
  88. Zhao, 2011, Sequence analysis of the P1 adhesin gene of Mycoplasma pneumoniae in clinical isolates collected in Beijing in 2008 to 2009, J. Clin. Microbiol., 49, 3000, 10.1128/JCM.00105-11 · DOI
  89. Zhao, 2013a, Multiple-locus variable-number tandem-repeat analysis of 201 Mycoplasma pneumoniae isolates from Beijing, China, from 2008 to 2011, J. Clin. Microbiol., 51, 636, 10.1128/JCM.02567-12 · doi:10.1128/jcm.02567-12
  90. Zhao, 2013b, Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012, Antimicrob. Agents Chemother., 57, 1521, 10.1128/AAC.02060-12 · DOI
  91. Zheng, 2015, Macrolide-resistant Mycoplasma pneumoniae, United States, Emerg. Infect. Dis., 21, 1470, 10.3201/eid2108.150273 · doi:10.3201/eid2108.150273
  92. Zhou, 2014, More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia, Antimicrob. Agents Chemother., 58, 1034, 10.1128/AAC.01806-13 · doi:10.1128/aac.01806-13
  93. Zhou, 2015, Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China, Antimicrob. Agents Chemother., 59, 1048, 10.1128/AAC.04308-14 · doi:10.1128/aac.04308-14

Cited by

Metadata

Authors
Pereyre, S., Goret, J., & Bébéar, C.
Venue
Frontiers in Microbiology
Published
2016-06-22
Volume
7
ISSN
1664-302X
Cited by
272
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.